Dianthus Therapeutics Inc
DNTH
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.49B
Close$
$-2.91
102.7% downside
Current Fair Value
102.7% downsideOvervalued by 102.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.49 Billion |
|---|---|
| Enterprise Value | $6.38 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.2 |
| Beta | 0.08 |
| Outstanding Shares | 56,029,124 |
Return
| Return on Equity | -2.55% |
|---|---|
| Return on Assets | -2.47% |
| Return on Invested Capital | -17.53% |
Valuation & Multiples
| P/E Ratio | -892 |
|---|---|
| PEG | -1517.97 |
| Price to Sales | - |
| Price to Book Ratio | 5.48 |
| Enterprise Value to Revenue | 4426.38 |
| Enterprise Value to EBIT | -30.86 |
| Enterprise Value to Net Income | -214 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.85
Average shareholder expectationRevenue Estimate
$297,182
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-1.02
Average shareholder expectationRevenue Estimate
$400,833
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 110.48% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 20.93%▼ 143.64% |
|---|---|
| Total Invested | $979.82M▼ 81.08% |
| Investors Holding | 75▼ 175.00% |
ESG Score
No data
About Dianthus Therapeutics Inc
81 employees
CEO: Jason Gardner magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of trans...